Hypertension and Diabetes Mellitus are common diseases that coexist at a greater frequency. Telmisartan is a Selective Angiotensin II Receptor Blocker which is used as first line agent in the treatment of hypertension. Telmisartan was also reported to activate Peroxisome Proliferator Activated Receptor gamma (PPAR-?) hence it provides greater beneficial effect on glucose metabolism than other ARBs. The main aim of this study is to evaluate the beneficial effect of Telmisartan compared to other anti-hypertensive among hypertensive patients with or without diabetes mellitus. It was a Prospective Comparative Observational study conducted for 6 months with 150 patients as per inclusion and exclusion criteria. Among the study population (n=150) 77 patients were male (51%), 73 were female(49%). The most prevalent age group was 60-70 (n=49- 32.66%). Most common co morbid conditions associated with hypertension were diabetes mellitus followed by kidney disease and dyslipidemia. According to JNC 8 classification 38.66% (n=58) patients fall in the category of Stage 1 Hypertension. Monotherapy was most frequently prescribed compared to combination therapy. There were significant reduction shown in patients treated with Telmisartan in both monotherapy and combination therapy. The reduction in Systolic blood pressure and diastolic blood pressure in patients treated with telmisartan monotherapy (n=27) were-27.34 mmHg and -7.81mmHg and in combination therapy (n=16) with telmisartan were -27.64mmHg and -12.1mmHg respectively. In monotherapy patients treated with telmisartan (n=27) had significant reduction of 54.56mg/dl in GRBS level and 38.54 mg/dl in FBS level. In combination therapy patients treated with Telmisartan and other antihypertensive (n=16) had a significant reduction of 30.62mg/dl in GRBS level and 22.12mg/dl in FBS level respectively